Andrew Cheng - Dec 7, 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Dec 7, 2023
Transactions value $
-$368,388
Form type
4
Date filed
12/11/2023, 08:59 PM
Previous filing
Oct 4, 2023
Next filing
Dec 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $42.6K +6.7K +1.45% $6.36 468K Dec 7, 2023 Direct F1
transaction AKRO Common Stock Sale -$134K -6.7K -1.43% $20.02 461K Dec 7, 2023 Direct F1, F2
transaction AKRO Common Stock Options Exercise $81.9K +12.9K +2.79% $6.36 474K Dec 8, 2023 Direct F1
transaction AKRO Common Stock Sale -$258K -12.9K -2.72% $20.01 461K Dec 8, 2023 Direct F1, F3
transaction AKRO Common Stock Award $0 +91.5K +19.86% $0.00 553K Dec 8, 2023 Direct F4
transaction AKRO Common Stock Options Exercise $47.1K +7.41K +1.34% $6.36 560K Dec 11, 2023 Direct F1
transaction AKRO Common Stock Sale -$148K -7.41K -1.32% $20.02 553K Dec 11, 2023 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -6.7K -16.75% $0.00 33.3K Dec 7, 2023 Common Stock 6.7K $6.36 Direct F1, F6
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -12.9K -38.66% $0.00 20.4K Dec 8, 2023 Common Stock 12.9K $6.36 Direct F1, F6
transaction AKRO Stock Option (Right to Buy) Award $0 +412K $0.00 412K Dec 8, 2023 Common Stock 412K $19.87 Direct F7
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -7.41K -36.25% $0.00 13K Dec 11, 2023 Common Stock 7.41K $6.36 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.05, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (5) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.03, inclusive.
F4 These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F5 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.13, inclusive.
F6 The options are vested and currently exercisable.
F7 This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.